Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:
Research and development programs	$ 5,043	$ 2,680
Product revenues	7,348	4,000
Total revenues	12,391	6,680
Costs and operating expenses:
Cost of product revenues	3,390	1,454
Research and development	20,835	13,720
Sales, general and administrative	20,607	14,866
Total costs and operating expenses	44,832	30,040
Loss from operations	(32,441)	(23,360)
Other income (expense):
Interest and other income, net	235	348
Interest expense	(1,347)	(1,871)
Loss from equity method investments	(3,834)	(959)
Gain from change in fair value of warrant liability	688	54
Gain (loss) from change in fair value of derivative liability	2,018	(737)
Total other income (expense)	(2,240)	(3,165)
Net loss	$ (34,681)	$ (26,525)
Net loss per share, basic and diluted	$ (0.50)	$ (0.43)
Weighted average number of common shares used in loss per share computation, basic and diluted	69,212,880	61,542,509